This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2016 Dec 23;22(1):6.

doi: 10.3390/molecules22010006.

Special Issue: New Approaches to Counteract Drug Resistance in Cancer

M Helena Vasconcelos^{1

2

3}

Affiliations

Affiliations

¹ i3S-Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Rua Alfredo Allen 208, Porto 4200-135, Portugal. hvasconcelos@ipatimup.pt.
² Cancer Drug Resistance Group, IPATIMUP-Institute of Molecular Pathology and Immunology of the University of Porto, Porto 4200-135, Portugal. hvasconcelos@ipatimup.pt.
³ Department of Biological Sciences, FFUP-Faculty of Pharmacy of the University of Porto, Rua de Jorge Viterbo Ferreira 228, Porto 4050-313, Portugal. hvasconcelos@ipatimup.pt.

PMID: 28025535
PMCID: PMC6155694
DOI: 10.3390/molecules22010006

Editorial

Special Issue: New Approaches to Counteract Drug Resistance in Cancer

M Helena Vasconcelos. Molecules. 2016.

. 2016 Dec 23;22(1):6.

doi: 10.3390/molecules22010006.

Author

M Helena Vasconcelos^{1

2

3}

Affiliations

¹ i3S-Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Rua Alfredo Allen 208, Porto 4200-135, Portugal. hvasconcelos@ipatimup.pt.
² Cancer Drug Resistance Group, IPATIMUP-Institute of Molecular Pathology and Immunology of the University of Porto, Porto 4200-135, Portugal. hvasconcelos@ipatimup.pt.
³ Department of Biological Sciences, FFUP-Faculty of Pharmacy of the University of Porto, Rua de Jorge Viterbo Ferreira 228, Porto 4050-313, Portugal. hvasconcelos@ipatimup.pt.

PMID: 28025535
PMCID: PMC6155694
DOI: 10.3390/molecules22010006

Abstract

n/a.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Similar articles

Marine Natural Products as Models to Circumvent Multidrug Resistance.
Long S, Sousa E, Kijjoa A, Pinto MM. Long S, et al. Molecules. 2016 Jul 8;21(7):892. doi: 10.3390/molecules21070892. Molecules. 2016. PMID: 27399665 Free PMC article. Review.
Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein.
Song JG, Lee YS, Park JA, Lee EH, Lim SJ, Yang SJ, Zhao M, Lee K, Han HK. Song JG, et al. Cancer Chemother Pharmacol. 2016 Oct;78(4):735-44. doi: 10.1007/s00280-016-3127-2. Epub 2016 Aug 12. Cancer Chemother Pharmacol. 2016. PMID: 27520631
Relevance of multidrug resistance in the age of targeted therapy.
Türk D, Szakács G. Türk D, et al. Curr Opin Drug Discov Devel. 2009 Mar;12(2):246-52. Curr Opin Drug Discov Devel. 2009. PMID: 19333870 Review.
Classical resistance mechanisms.
Jäeger W. Jäeger W. Int J Clin Pharmacol Ther. 2009 Jan;47(1):46-8. Int J Clin Pharmacol Ther. 2009. PMID: 19203536 No abstract available.
Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H, Siddig S, Uzu M, Suzuki S, Nomura Y, Kashiba T, Gushimiyagi K, Sekine Y, Uehara T, Arano Y, Yamaura K, Ueno K. Sato H, et al. Eur J Pharmacol. 2015 Jan 5;746:258-66. doi: 10.1016/j.ejphar.2014.11.021. Epub 2014 Nov 29. Eur J Pharmacol. 2015. PMID: 25455500

See all similar articles

References

1. Xavier C.P., Pesic M., Vasconcelos M.H. Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line Models. Curr. Cancer Drug Targets. 2016;16:226–237. doi: 10.2174/1568009616666151113120705. - DOI - PubMed
1. Venkatesan S., Swanton C. Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome. Am. Soc. Clin. Oncol. Educ. Book. 2016;35:e141-9. doi: 10.14694/EDBK_158930. - DOI - PubMed
1. Freitas D.P., Teixeira C.A., Santos-Silva F., Vasconcelos M.H., Almeida G.M. Therapy-induced enrichment of putative lung cancer stem-like cells. Int. J. Cancer. 2014;134:1270–1278. doi: 10.1002/ijc.28478. - DOI - PubMed
1. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006;5:219–234. doi: 10.1038/nrd1984. - DOI - PubMed
1. Du B., Shim J.S. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. Molecules. 2016;21:965. doi: 10.3390/molecules21070965. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- The YODA Project